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Impairment of apoptosis is a hallmark of cancer and can
result in resistance to chemotherapy. Tumour resistance
to apoptosis is frequently acquired through deregulated
expression of BCL-2 family members or inactivation of
the p53 tumour suppressor pathway. Over-expression of
the pro-survival protein BCL-2 is common in breast
cancer (where it is readily detected by immunostaining),
and has been shown to be an important prognostic mar-
ker. A potential role for BCL-2 as a therapeutic target in
breast cancer, however, has not been explored. Recently,
small molecules termed ‘BH3-mimetics’ have been
developed that mimic the action of pro-apoptotic BH3-
only proteins. These bind and neutralize pro-survival
proteins including BCL-2.
Tissue microarrays containing 197 primary breast
tumours were evaluated for the expression of BCL-2, its
anti-apoptotic relatives MCL-1 and BCL-XL, and the
pro-apoptotic BH3-only ligand BIM. These proteins
were co-expressed at relatively high levels in a substan-
tial proportion of heterogeneous breast tumours, includ-
ing clinically aggressive basal-like cancers. To determine
whether the BH3-mimetic ABT-737 that neutralizes
BCL-2, BCL-XL and BCL-W, had potential efficacy in
targeting BCL-2-expressing basal-like triple negative
tumours, we generated a panel of primary breast tumour
xenografts in immunocompromised mice and treated
recipients with either ABT-737, docetaxel or a combina-
tion. Tumour response and overall survival were signifi-
cantly improved by combination therapy, but only for
tumour xenografts that expressed elevated levels of
BCL-2. Treatment with ABT-737 alone was ineffective,
suggesting that ABT-737 sensitizes the tumour cells to
docetaxel. Combination therapy was accompanied by a
marked increase in apoptosis and dissociation of BIM
from BCL-2. Notably, BH3-mimetics also appeared
effective in BCL-2-expressing xenograft lines that har-
bored p53 mutations.
In summary, primary breast tumour xenograft models
that recapitulate the phenotype of the primary tumour
have been developed as useful ‘proof-of-principle’,p r e -
clinical models. Our findings provide the first in vivo
evidence that BH3-mimetics can be used to sensitize
primary BCL-2-expressing breast tumours to taxane
chemotherapy. Our results suggest that elevated BCL-2
expression constitutes a predictive response marker in
breast cancer. These findings provide a rationale for the
development of clinical protocols using the oral analo-
gue ABT-263 (navitoclax) as an adjunct to taxane che-
motherapy in BCL-2-expressing basal-like and luminal
breast cancer.
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